Results 91 to 100 of about 19,412 (203)

Surfaceome Reprogramming of Stemsomes Promotes Lung Cancer Targeting via Potentiated Receptor–Ligand Interactions

Advanced Science, Volume 13, Issue 51, 14 September 2026.
This study presents a surfaceome‐reprogramming strategy for mutation‐independent lung cancer therapy by repurposing dexamethasone to prime mesenchymal stem cell‐derived nanovesicles. The engineered vesicles leverage multi‐valent interactions mediated by upregulated adhesion proteins, EPHA2, and NOTCH3.
Geunhye Kim, In Ah Kwon, Bo Seop Jeong, Hyo Seon Kim, Joo‐Hwan Park, Sung Jean Park, Sang‐Rae Lee, Youngki Lee, Dongwoo Khang   +8 more
wiley   +1 more source

A Multikinase Inhibitor AX-0085 Blocks FGFR1 Activation to Overcomes Osimertinib Resistance in Non-Small Cell Lung Cancer

Biomedicines
Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with high efficacy in treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations.
Byung-Ho Rhie, Janardhan Keshav Karapurkar, Hyun-Yi Kim, Sang Hyeon Woo, D. A. Ayush Gowda, Dong Ha Kim, Myeong Jun Choi, Young Jun Park, Viswanathaiah Matam, Yoonki Hong, Seok-Ho Hong, Suresh Ramakrishna, Kye-Seong Kim   +12 more
doaj   +1 more source

CauFinder: Steering Cell‐State and Phenotype Transitions by Causal Disentanglement Learning

Advanced Science, Volume 13, Issue 51, 14 September 2026.
CauFinder combines causal disentanglement modeling and network control to prioritize causal drivers of cell‐state transitions from observational transcriptomic data. The framework separates transition‐relevant signals from spurious associations, nominates intervention targets across biological and disease contexts, and identifies DAAM1 as an actionable
Chengming Zhang, Zexi Chen, Yuanxiang Miao, Zuolin Shen, Deyu Cai, Shijie Tang, Yun Xue, Weifeng Guo, Hongbin Ji, Jian Liu, Kazuyuki Aihara, Luonan Chen   +11 more
wiley   +1 more source

MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma

Scientific Reports
Overcoming resistance to epidermal growth factor receptor tyrosine kinase inhibitors, including osimertinib, is urgent to improve lung cancer treatment outcomes.
Takuya Shintani, Yu-Ting Shun, Yuji Toyozumi, Kenji Ikemura, Takayuki Shiroyama, Izumi Nagatomo, Kentaro Jingushi, Yoshito Takeda, Atsushi Kumanogoh, Masahiro Okuda   +9 more
doaj   +1 more source

4‐Hydroxytamoxifen induces a noncanonical ferroptosis in lung adenocarcinoma by targeting AKR1B10

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
4‑OHT directly inhibits AKR1B10 enzymatic activity to induce noncanonical ferroptosis in LUAD. AKR1B10 sustains LUAD survival by stabilising ACC1 and detoxifying reactive carbonyl species (RCSs). Nanatinostat similarly targets AKR1B10 and elicits the same cell death modality.
Hui Yang, Yanan Wang, Jiangbo Jin, Hanyan Xu, Yinshui Miao, Xiaojing Wu, Shengsong Chen, Tianyu Han, Qingyuan Zhan   +8 more
wiley   +1 more source

Early Local Treatment Delays Multiple Metastases in Non‐Small Cell Lung Cancer With Solitary Distant Metastasis: A Multicenter Retrospective Cohort Study

MedComm, Volume 7, Issue 9, September 2026.
In NSCLC patients with solitary distant metastasis (SDM), early local treatment significantly delays the progression to multi‐metastasis by 14 months (HR = 0.55) compared to delayed or no treatment. This multicenter cohort study highlights SDM as an indolent state, emphasizing the critical time window for effective local intervention. .
Kang Miao, Siyu Lei, Xiaobin Zheng, Shanshan Yang, Yujing Li, Sihui Chen, Qian Miao, Longfeng Zhang, Zihua Zou, Haipeng Xu, Gen Lin   +10 more
wiley   +1 more source

Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib [PDF]

Background Osimertinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat patients with epidermal growth factor receptor–mutant non–small-cell lung cancer.
Tatebe, Yasuhisa, Murakawa, Kiminaka, Higashionna, Tsukasa, Zamami, Yoshito, Tanaka, Yuta, Manabe, Yohei, Hamano, Hirofumi, Okano, Shinobu   +7 more
core   +1 more source

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells

Molecules, 2016
In recent years, tyrosine kinase inhibitors (TKIs) have been shown capable of inhibiting the ATP-binding cassette (ABC) transporter-mediated multidrug resistance (MDR). In this study, we determine whether osimertinib, a novel selective, irreversible EGFR
Xiao-Yu Zhang, Yun-Kai Zhang, Yi-Jun Wang, Pranav Gupta, Leli Zeng, Megan Xu, Xiu-Qi Wang, Dong-Hua Yang, Zhe-Sheng Chen   +8 more
doaj   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, Volume 15, Issue 3, Page 206-226, September 2026.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) [PDF]

Faustine X Luo,1,2 Zhaohui Arter,1,2 Sai-Hong Ignatius Ou,1,2 Misako Nagasaka1– 3 1Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA; 2University of California Irvine School of Medicine, Orange, CA, 92868, USA; 3St.
Nagasaka M, Arter Z, Luo FX, Ou SI
core